Nvron Life Science Ltd
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)
Metviron Trio 1 Tablet ER is a combination of three antidiabetic medicines used to treat type 2 diabetes mellitus in adults.
Tablet ER
Metviron Trio 1 Tablet ER belongs to a category of medicines known as anti-diabetic drugs. It is a combination of medicines used to treat type 2 diabetes mellitus in adults. It helps control blood sugar levels in people with diabetes.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Metviron Trio 1 Tablet ER is to be taken empty stomach.
No common side effects listed.
It is unsafe to consume alcohol with Metviron Trio 1 Tablet ER.
Metviron Trio 1 Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Metviron Trio 1 Tablet ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Metviron Trio 1 Tablet ER is a combination of three antidiabetic medicines:
Take it with food to lower your chance of having an upset stomach. It can cause hypoglycemia (low blood sugar level) when used with other antidiabetic medicines alcohol or if you delay or miss a meal. Carry a sugar source with you for immediate relief. Your doctor may check your liver function regularly. Inform your doctor if you develop symptoms such as abdominal pain loss of appetite or yellowing of the eyes or skin (jaundice).
Metviron Trio 1 Tablet ER contains three active ingredients: Glimepiride, Metformin, and Voglibose. It's prescribed to treat type 2 diabetes mellitus (DM). This medication improves blood glucose levels in adults when used with proper diet and exercise. Glimepiride lowers blood glucose by increasing insulin release from the pancreas. Metformin reduces glucose production from the liver and enhances insulin sensitivity. Voglibose is an alpha-glucosidase inhibitor, lowering postprandial (after meal) glucose levels. This medication is not suitable for Type 1 DM treatment.
Common side effects include hypoglycemia (low blood sugar), nausea, diarrhea, altered taste, flatulence, stomach pain, headache, skin rash, and respiratory tract infection. If you experience any unusual or severe reactions, seek immediate medical help.
Metviron Trio 1 Tablet ER is contraindicated for patients with known allergies to any of its components or excipients. Avoid use in those with moderate to severe kidney disease, inflammatory bowel disease, colonic ulcerations, or underlying metabolic acidosis including diabetic ketoacidosis.
No. Combining Metviron Trio 1 Tablet ER with alcohol is not recommended. It can lower blood sugar levels further and increase the risk of lactic acidosis.
Yes, Metviron Trio 1 Tablet ER can cause hypoglycemia (low blood sugar). Symptoms include nausea, headache, irritability, hunger, sweating, dizziness, fast heart rate, and feeling anxious or shaky. This is more likely if you miss meals, drink alcohol, over-exercise, or use other antidiabetic medications simultaneously. Regular monitoring of blood sugar level is important.
Store this medication in its original packaging, tightly sealed. Follow the instructions on the label for storage and disposal. Do not share it with pets or children. If unused, discard responsibly.